Biodesix, Inc.
Biodesix, Inc. (BDSX) Financial Performance & Income Statement Overview
Explore the financials of Biodesix, Inc. (BDSX), including yearly and quarterly data on income, cash flow, and balance sheets.
Biodesix, Inc. (BDSX) Income Statement & Financial Overview
View the income breakdown for Biodesix, Inc. BDSX across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $17.96M | $20.43M | $18.15M | $17.93M |
| Cost of Revenue | $3.70M | $4.34M | $4.18M | $3.88M |
| Gross Profit | $14.26M | $16.09M | $13.97M | $14.05M |
| Gross Profit Ratio | $0.79 | $0.79 | $0.77 | $0.78 |
| R&D Expenses | $2.87M | $2.41M | $2.55M | $2.56M |
| SG&A Expenses | $20.45M | $20.22M | $20.02M | $19.66M |
| Operating Expenses | $23.39M | $22.74M | $22.56M | $22.22M |
| Total Costs & Expenses | $27.09M | $27.08M | $26.74M | $26.09M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $1.69M | $1.75M | $2.04M | $1.94M |
| Depreciation & Amortization | $1.41M | $1.40M | $1.42M | $1.32M |
| EBITDA | -$8.01M | -$5.10M | -$6.80M | -$7.55M |
| EBITDA Ratio | -$0.45 | -$0.25 | -$0.37 | -$0.42 |
| Operating Income | -$9.14M | -$6.65M | -$8.59M | -$8.17M |
| Operating Income Ratio | -$0.51 | -$0.33 | -$0.47 | -$0.46 |
| Other Income/Expenses (Net) | -$1.97M | -$1.60M | -$1.67M | -$2.57M |
| Income Before Tax | -$11.10M | -$8.25M | -$10.26M | -$10.81M |
| Income Before Tax Ratio | -$0.62 | -$0.40 | -$0.57 | -$0.60 |
| Income Tax Expense | $0.00 | -$1.28M | $0.00 | $0.00 |
| Net Income | -$11.10M | -$8.25M | -$10.26M | -$10.81M |
| Net Income Ratio | -$0.62 | -$0.40 | -$0.57 | -$0.60 |
| EPS | -$0.08 | -$0.06 | -$0.07 | -$0.09 |
| Diluted EPS | -$0.08 | -$0.06 | -$0.07 | -$0.09 |
| Weighted Avg Shares Outstanding | $146.55M | $129.67M | $146.30M | $127.17M |
| Weighted Avg Shares Outstanding (Diluted) | $146.55M | $129.67M | $146.30M | $127.17M |
Financial performance has remained strong, with revenue growing from $17.93M in Q2 2024 to $17.96M in Q1 2025. Gross profit continued to perform well, with margins at 79% in the latest quarter. Operating income reached -$9.14M in Q1 2025, holding a steady -51% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$8.01M. Net income dropped to -$11.10M, keeping EPS at -$0.08. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan